NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, Enters Into a Manufacturing Agreement With ImmunoCellular Therapeutics, Ltd. for Dendritic Cell Vaccines Targeting Brain and Other Cancers
6/3/2013 9:37:20 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALLENDALE, N.J. and LOS ANGELES, June 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), its subsidiary, Progenitor Cell Therapy LLC ("PCT"), and ImmunoCellular Therapeutics, Ltd. (NYSE MKT:IMUC) ("IMUC"), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today the execution of a Services Agreement under which PCT will provide cGMP ("current good manufacturing practices") manufacturing services to support research and development of IMUC's ICT-121 cell therapy product candidate, a dendritic cell vaccine targeting CD133 cells. PCT currently provides manufacturing services for IMUC's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma, for its Phase II clinical trial.
Help employers find you! Check out all the jobs and post your resume.